This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Conclusion”Comparsion of the Bieoquvalence of Generic Versus Branded Clozapine”

Larry Ereshefsky, PharmD; William M. Glazer, MD

Published: April 1, 2001

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Clozapine, the first atypical antipsychotic, has been marketed in the United States since 1989. Its usage has been restricted to those patients with persistent psychotic or bipolar disorder who are considered treatment resistant and who are intolerant of standard antipsychotic therapies. Clozapine has also been found to be the least likely of the antipsychotics to worsen previously diagnosed tardive dyskinesia.1 With the expiration of Novartis’s patent for Clozaril in 1998, generic products have now begun to be marketed.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: